Monopar Therapeutics (id:6082 MNPR)
20.10 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 3:21:29 PM)
Exchange closed, opens in 1 day 18 hours
About Monopar Therapeutics
Market Capitalization 106.08M
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.
| Headquarters (address) |
1000 Skokie Boulevard Wilmette 60091 IL United States |
| Phone | 847 388 0349 |
| Website | https://www.monopartx.com |
| Employees | 9 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | MNPR |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.37 - 38.50 |
| Market Capitalization | 106.08M |
| P/E trailing | -6.59 |
| P/E forward | -8.52 |
| Price/Book | 10.72 |
| Beta | 1.10 |
| EPS | -1.98 |
| EPS United States (ID:6, base:3402) | 24.25 |